Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-24T17:20:39.465Z Has data issue: false hasContentIssue false
  • English
  • Français

Toxicity of lofepramine in heart disease

Published online by Cambridge University Press:  13 June 2014

Bankole A Johnson ,
Jacinta McCann  and
Efunbowale A Johnson
Bankole A Johnson
Affiliation:
Warneford Hospital, Warneford Lane, Headington, Oxford OX3 7JX.
Jacinta McCann
Affiliation:
Warneford Hospital, Warneford Lane, Headington, Oxford OX3 7JX.
Efunbowale A Johnson
Affiliation:
St. Mary's Hospital, Praed Street, London W2.
Get access Rights & Permissions [Opens in a new window]

Abstract

Lofepramine at the upper limit of its therapeutic range (210mg/day), was associated with the development of sinus tachycardia with atrial ectopic beats and progression of right bundle branch block to trifascicular block in an 82 year old man with a history of heart disease. As with any antidepressant administered in a high therapeutic dose, caution and regular electrocardiographic monitoring of elderly patients with heart disease receiving lofepramine is recommended.

Type
Clinical and Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 7 , Issue 2 , September 1990 , pp. 142 - 143
Copyright
Copyright © Cambridge University Press 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Leonard, B. A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review. Int Clin Psychopharmacol, 1987; 2: 281–297.CrossRefGoogle ScholarPubMed
2.Wright, SHerrmann, L. Double blind comparative study of the effects of lofepramine and amitryptyline in depressed outpatients. Arzneimittel Forschung 1976; 26: 1167–1169.Google Scholar
3.Foltyn, P. The treatment of depressive conditions in elderly patient. Arztliche Praxis 1979; 96: 3963.Google Scholar
4.Gökelma, Y. Heart effects of lofepramine in depressed patients with and without heart disease, 1983. Presented at the VIIth World Congress of Psychiatry, Vienna.Google Scholar
5.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed (revised). Washington DC: American Psychiatric Association, 1987.Google Scholar
6.Beck, A, Ward, C, Mendelson, M. An inventory for measuring depression. Arch Gen Psychiatry 1961; 51: 343–345.Google Scholar
7.Beck, A, Weissman, A, Lester, D, et al.The measurement of pessimism: the Hopelessness Scale. J Consult Clin Psychol 1974b; 42: 861–865.CrossRefGoogle ScholarPubMed
8.Beaumont, G. Suicide and antidepressant overdosage in General Practice. Br J Psychiatry 1989; 155 (supplement 6): 27–31.CrossRefGoogle Scholar
9.Weatherall, D, Leadingham, J, Warrell, D. Oxford textbook of medicine. 2nd ed. Oxford: Oxford University Press, 1983.Google Scholar
10.Plym Forshell, G, Siwers, B, Tuck, JR. Pharmacokinetics of lofepramine in man: relationship of inhibition of noradrenaline uptake. European Journal of Clinical Pharmacology 1976: 9: 291–298.CrossRefGoogle Scholar